Alpha 2.0
Login Register
» Authors » Despoina N Maritsi

Despoina N Maritsi

Explore the profile of Despoina N Maritsi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 21
Citations 42
Followers 0
Related Specialties
Rheumatology
Pediatrics
Biomedical Engineering
Top 10 Co-Authors
Maria N Tsolia
George Vartzelis
Nikos Spyridis
Lydia Kossiva
Stayroula Papailiou
Ioannis Kopsidas
Adrianos Nezos
Lida Mentesidou
Anastasia Garoufi
Despina Eleftheriou
Published In
Rheumatology (Oxford)
Arthritis Rheumatol
J Clin Rheumatol
Pediatr Int
Clin Exp Rheumatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Antibody status against measles and rubella in juvenile localized scleroderma patients on synthetic DMARDs: a prospective case-control study
Maritsi D, Kopsidas I, Tsagkli P, Tsolia M
Rheumatology (Oxford) . 2024 Mar; 63(SI2):SI270-SI272. PMID: 38498836
No abstract available.
2.
Measles-specific antibodies loss after a single dose of MMR vaccine in children with oligo-articular JIA on methotrexate treatment: a single-center case-controlled study
Kopsidas I, Mentesidou L, Syggelou A, Papadimitriou M, Matsas M, Kossiva L, et al.
Rheumatol Int . 2024 Mar; 44(12):3027-3033. PMID: 38498151
Novel treatments have revolutionized the care and outcome of patients with juvenile idiopathic arthritis (JIA). Patients with rheumatic diseases are susceptible to infections, including vaccine preventable ones, due to waning...
3.
Achieving inactive disease in enthesitis-related arthritis with secukinumab following TNF-inhibitor failure
Papailiou S, Onoufriou M, Mentesidou L, Syggelou A, Tsolia M, Maritsi D
Rheumatology (Oxford) . 2023 Dec; 63(11):e297-e298. PMID: 38058199
No abstract available.
4.
Immunogenicity 6 months post COVID-19 mRNA vaccination among adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors
Dimopoulou D, Tsolia M, Spyridis N, Maritsi D
Rheumatology (Oxford) . 2022 Jul; 62(SI2):SI205-SI209. PMID: 35788275
Objectives: Mass vaccination is the most effective strategy for controlling the COVID-19 pandemic. This study aimed to evaluate the 6-month immunogenicity after BNT162b2-COVID-19 vaccination in adolescents with JIA on TNFi...
5.
Safety and tolerability of the COVID-19 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors
Dimopoulou D, Spyridis N, Vartzelis G, Tsolia M, Maritsi D
Arthritis Rheumatol . 2021 Sep; 74(2):365-366. PMID: 34492161
No abstract available.
6.
Attainment of Inactive Disease Following Discontinuation of Adalimumab Monotherapy in Patients With Enthesitis-Related Arthritis: A Real-Life, Dual-Center Experience
Papailiou S, Dasoula F, Tsolia M, Maritsi D
J Clin Rheumatol . 2021 Jun; 28(2):e616-e618. PMID: 34145201
No abstract available.
7.
Diagnosis and Management of a Young Girl With Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) Linked to a Novel Mutation
Klinaki E, Nezos A, Tzioufas A, Tsolia M, Maritsi D
Cureus . 2020 Nov; 12(10):e10766. PMID: 33154839
A nine-year-old girl with a two-month history of fever and generalized malaise, along with intermittent abdominal pain, immigrant myalgia, throat pain, anorexia, and long-standing failure to thrive, was admitted to...
8.
Discontinuation of Canakinumab following Clinical Disease Remission Is Feasible in Patients with Systemic Juvenile Idiopathic Arthritis
Maritsi D, Vougiouka O, Eleftheriou D
J Rheumatol . 2020 Feb; 47(4):634-635. PMID: 32062604
No abstract available.
9.
A National Survey Across Primary Care Pediatricians Regarding Immunization Views and Practices in Children With Rheumatic Diseases
Papailiou S, Markade A, Eleftheriou I, Tsolia M, Garoufi A, Maritsi D
J Clin Rheumatol . 2020 Jan; 27(8):e588-e590. PMID: 31972735
Methods: Cross-sectional survey conducted with an anonymous questionnaire of 34 items distributed to pediatricians via an online platform. Four hundred questionnaires were sent, and 256 were returned and analyzed using...
10.
Molecular and clinical spectrum of four pedigrees of TRAPS in Greece: results from a national referral center
Nezos A, Argyropoulou O, Klinaki E, Marketos N, Karagianni P, Eliopoulos E, et al.
Rheumatology (Oxford) . 2019 Sep; 59(6):1241-1246. PMID: 31562507
Objective: Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is a rare autosomal dominantly inherited autoinflammatory disease caused by mutations of the TNFRSF1A gene. To address the association between TNFRSF1A mutations...